Skip to main content
editorial
. 2017 Aug 29;6(4):253–263. doi: 10.1159/000479573

Table 4.

Possible reasons for not achieving superiority

- AFP imbalance favoring sorafenib arm
- Hepatitis C-related HCC imbalance favoring for sorafenib arm
- By excluding patients with main portal vein tumor thrombus and tumor burden ≥50%, patients were relatively good prognostic population in both arms, leading to long postprogression survival (PPS) who likely received post trial treatments
- OS benefit was diluted by long PPS